Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects

Participants undergo two study periods in randomized order: 14 days of escitalopram (10 mg x7 then 20 mg x7) or placebo pretreatment, each followed by a single 25 mg oral psilocybin session.

Primary outcome is subjective effects on consciousness measured by the 5D-ASC total score; secondary outcomes include additional psychological instruments, plasma concentrations of psilocybin and escitalopram, HTR gene expression and safety measures (autonomic effects, ECG).